经肝动脉介入治疗肝转移癌的疗效分析

目的 评价经肝动脉介入治疗(TAIT)在肝转移癌综合治疗中的价值,探讨影响患者预后的因素.方法 回顾性分析中国医学科学院肿瘤医院1997年1月至2000年6月收治的470例肝转移癌患者共行TAIT 1231例次的临床资料,观察其近期、远期疗效和毒副作用,评价TAIT对肝转移癌患者的疗效,采用Cox回归模型分析可能影响患者预后的因素.结果 470例患者中有94例完全缓解,143例部分缓解,总有效率为50.4%(237/470),中位生存时间为13.5个月,0.5、1、2、3、5年生存率分别为86.4%、66.8%、35.6%、16.9%、7.3%,全组无严重并发症发生.原发肿瘤是否切除、肿瘤血供状况、肝转移癌是单发还是多发、有无门静脉栓塞、TAIT后是否行辅助化疗、原发肿瘤是否为乳腺癌、肿瘤是否累及多个肝叶、TAIT前是否伴有其他部位转移是影响患者预后的8项因素(X2=17.322,12.593,8.721,8.573,8.492,7.838,5.623,5.463,P<0.05).结论 TAIT对不能手术的肝转移癌是一种有效姑息性治疗方法.原发肿瘤已切除、肿瘤血供丰富、孤立性肝转移癌、肿瘤仅累及单个肝叶、无门静脉栓塞、原发肿瘤为乳腺癌、TAIT后行辅助化疗、无其他部位转移的患者,TAIT疗效较好.

Efficacy of transarterial interventional therapy in the treatment of metastatic liver cancer

Objective To evaluate the efficacy of transarterial interventional therapy (TAIT) in treating patients with metastatic liver cancer, and to investigate the factors influencing the prognosis of patients. Methods From January 1997 to June 2000, 470 patients with metastatic liver cancer had undergone TAIT 1231 times in the Cancer Hospital of the Chinese Academy of Medical Sciences. The clinical data of the patients were retrospectively analyzed. The short-term and long-term efficacy and the side effect of TAIT were assessed. The potential factors influencing the prognosis of the patients were determined by Cox regression analysis. Results Complete remission was observed in 94 patients, and partial remission in 143. The total effective rate was 50.4% (237/470). The median survival time was 13.5 months. The O. 5-, 1-, 2-, 3-, 5-year survival rates were 86.4%, 66. 8%, 35.6%, 16.9%, 7.3%, respectively. No severe complication occurred. The factors influencing the prognosis of the patients were: the resection of the primary tumor, blood supply of the tumor, multiple metastases of liver cancer, thrombus in the portal vein, adjuvant chemotherapy after TAIT, tumor originated from breast cancer, tumors invading multiple lobes, concurrent metastasis in other sites (X2= 17. 322, 12. 593, 8.721, 8.573, 8.492, 7. 838, 5. 623, 5. 463, P < 0.05). Conclusions TAIT is an effective palliative therapy for metastatic liver cancer which cannot be resected. The factors mentioned above influence the prognosis of patients after TAIT.